Press release
Brain Metastasis from Breast Cancer Pipeline Analysis 2024: Clinical Trials, FDA, EMA, PMDA Approvals, Emerging Therapies, and Growth Prospects
DelveInsight's, "Brain Metastasis from Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Brain Metastasis from Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Key Takeaways from the Brain Metastasis from Breast Cancer Pipeline Report
* DelveInsight's Brain Metastasis from Breast Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Brain Metastasis from Breast Cancer treatment.
* The leading Brain Metastasis from Breast Cancer Companies such as Angiochem Inc., Novartis, Merck Sharp & Dohme Corp., AstraZeneca, Criterium, Inc., Bristol-Myers Squibb, Bayer, Northwest Biotherapeutics, Array BioPharma, and others.
* Promising Brain Metastasis from Breast Cancer Therapies such as Lapatinib, Herceptin, Efaproxiral, Vinorelbine, afatinib, and others
* May 2024: Baptist Health South Florida- Phase 1 Trial of Tucatinib, Trastuzumab, and Capecitabine With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From HER-2 Positive Breast Cancer. This research study will evaluate how well brain metastases associated with HER-2 positive breast cancer can be controlled using a type of radiation known as stereotactic radiosurgery (SRS) when combined with three therapeutic agents, tucatinib, capecitabine, and trastuzumab.
* May 2024:- MedSIR- Multicenter, Single-arm, 3 Cohort, Phase II Trial of HER3-DXd in Patients With Active Brain Metastases From Metastatic Breast Cancer and Non-small Cell Lung Cancer, and in Patients With Leptomeningeal Disease From Advanced Solid Tumors. The goal of this phase II clinical trial] is to analyze the efficacy of patritumab deruxtecan (HER3-DXd) in patients with metastatic breast cancer (MBC) or advanced non-small cell lung cancer (aNSCLC) with active brain metastases (BM) who have received at least one line of systemic therapy in the advanced setting, or patients with active leptomeningeal carcinomatosis/disease (LMD) after radiotherapy from an advanced solid tumor who do not need immediate local treatment, and have not received prior treatment with an anti-HER3 targeted drug].
Request a sample and discover the recent advances in Brain Metastasis from Breast Cancer Treatment Drugs @ Brain Metastasis from Breast Cancer Pipeline Report [https://www.delveinsight.com/sample-request/brain-metastasis-from-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Brain Metastasis from Breast Cancer Overview
Central nervous system or brain metastases traditionally occur in 10-16% of metastatic breast cancer patients and are associated with a dismal prognosis. The development of brain metastases has been associated with young age, and tumors that are estrogen receptor negative, Her-2+ or of the basal phenotype. Diagnosis can be done through MRI (magnetic resonance imaging) study of the brain.In rare cases, biopsies are performed to confirm the diagnosis.
Neuroimaging, staging, and diagnostic neuropathology can also be done. Treatment typically includes whole brain irradiation, or either stereotactic radiosurgery or surgery with whole brain radiation, resulting in an approximately 20% one year survival. The blood-brain barrier is a formidable obstacle to the delivery of chemotherapeutics to the brain. Under chemotherapy, etirinotecan pegol has promising results and in Abemaciclib as a targeted therapies can also be seen. Lapatinib, a small molecule with potential ability to cross the BBB, has been extensively tested in the treatment of HER2-positive brain metastases.
Brain Metastasis from Breast Cancer Emerging Drugs Profile
* ANG1005: Angiochem
ANG-1005 is a peptide-drug conjugate containing paclitaxel covalently linked to a peptide (Angiopep-2). The drug gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the Blood brain barrier. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain. A Phase III clinical trial is evaluating ANG-1005 to treat brain metastasis associated with breast cancer.
* Pembrolizumab: Merck Sharp & Dohme
Pembrolizumab is a medication used in the management and treatment of various oncologic conditions. It is in the cancer immunotherapy class of drugs. KEYTRUDA binds to the PD-1 receptor, blocking both immune-suppressing ligands, PDL1 and PDL2, from interacting with PD-1 to help restore T-cell response and immune response. The drug is currently being evaluated in Phase I/II stage of development for the treatment of patients with Brain Metastases In Breast Cancer Patients.
Learn more about Brain Metastasis from Breast Cancer in clinical trials @ Brain Metastasis from Breast Cancer Drugs [https://www.delveinsight.com/sample-request/brain-metastasis-from-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Brain Metastasis from Breast Cancer Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Brain Metastasis from Breast Cancer. The companies which have their Brain Metastasis from Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Angiochem.
DelveInsight's Brain Metastasis from Breast Cancer Pipeline Report covers around 10+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration
Discover more about Brain Metastasis from Breast Cancer in development @ Brain Metastasis from Breast Cancer Clinical Trials [https://www.delveinsight.com/sample-request/brain-metastasis-from-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Brain Metastasis from Breast Cancer Companies
Angiochem Inc., Novartis, Merck Sharp & Dohme Corp., AstraZeneca, Criterium, Inc., Bristol-Myers Squibb, Bayer, Northwest Biotherapeutics, Array BioPharma, and others.
Brain Metastasis from Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
* Molecule Type
Brain Metastasis from Breast Cancer Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
To know more about Brain Metastasis from Breast Cancer, visit @ Brain Metastasis from Breast Cancer Segmentation [https://www.delveinsight.com/sample-request/brain-metastasis-from-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Brain Metastasis from Breast Cancer Pipeline Report
* Coverage- Global
* Brain Metastasis from Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Brain Metastasis from Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Brain Metastasis from Breast Cancer Companies- Angiochem Inc., Novartis, Merck Sharp & Dohme Corp., AstraZeneca, Criterium, Inc., Bristol-Myers Squibb, Bayer, Northwest Biotherapeutics, Array BioPharma, and others.
* Brain Metastasis from Breast Cancer Therapies- Lapatinib, Herceptin, Efaproxiral, Vinorelbine, afatinib, and others
For further information on the Brain Metastasis from Breast Cancer Pipeline Therapeutics, reach out @ Brain Metastasis from Breast Cancer Products Development [https://www.delveinsight.com/sample-request/brain-metastasis-from-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Brain Metastasis from Breast Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* ANG1005: Angiochem
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early stage products (Phase I)
* Pembrolizumab: Merck Sharp & Dohme
* Drug profiles in the detailed report.....
* Inactive Products
* Brain Metastasis from Breast Cancer Key Companies
* Brain Metastasis from Breast Cancer Key Products
* Brain Metastasis from Breast Cancer- Unmet Needs
* Brain Metastasis from Breast Cancer- Market Drivers and Barriers
* Brain Metastasis from Breast Cancer- Future Perspectives and Conclusion
* Brain Metastasis from Breast Cancer Analyst Views
* Brain Metastasis from Breast Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=brain-metastasis-from-breast-cancer-pipeline-analysis-2024-clinical-trials-fda-ema-pmda-approvals-emerging-therapies-and-growth-prospects]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Brain Metastasis from Breast Cancer Pipeline Analysis 2024: Clinical Trials, FDA, EMA, PMDA Approvals, Emerging Therapies, and Growth Prospects here
News-ID: 3526028 • Views: …
More Releases from ABNewswire
![Gene Therapies For Cardiomyopathies Market Growth Anticipated by 2032 | Companies includes Lexeo Therapeutics, expected to boost the market](https://cdn.open-pr.com/X/9/X912974801_g.jpg)
Gene Therapies For Cardiomyopathies Market Growth Anticipated by 2032 | Companie …
Gene Therapies For Cardiomyopathies Market Growth is expected due to increased interest from companies in developing new gene therapies, advancements in diagnostic techniques, and the anticipated introduction of emerging therapies during the forecast period.
According to the latest report titled "Gene Therapies for Cardiomyopathies Market Insights, Epidemiology, and Market Forecast 2032 [https://www.delveinsight.com/report-store/gene-therapies-for-cardiomyopathies-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" from DelveInsight, the Gene Therapies for Cardiomyopathies market is projected to experience significant growth from 2019 to 2032. This…
![Cascade Web Solutions: Elevating Digital Presence for Local Businesses in the Pacific Northwest](https://cdn.open-pr.com/X/9/X912350736_g.jpg)
Cascade Web Solutions: Elevating Digital Presence for Local Businesses in the Pa …
Cascade Web Solutions, based in Tri-Cities, WA, provides custom web development and local SEO services using advanced technologies like Next.js and React. They create high-performance websites that enhance user experience and search engine rankings. Known for affordability and transparent pricing, they offer tailored solutions to boost online visibility for businesses. With a client-centric approach and proven results, Cascade Web Solutions helps businesses achieve their digital goals.
Tri-Cities, WA - Cascade Web…
![Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (OSTX, ATNM, CRBP, PBYI)](https://cdn.open-pr.com/X/9/X912877158_g.jpg)
Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (OSTX, ATNM, …
In oncology, the relentless drive for innovation is forging new paths in cancer treatment. The field is rapidly evolving with advances in targeted therapies, immunotherapies, and novel technologies, each promising to reshape patient outcomes. Let's explore some standout companies that are leading the charge in this transformative era of cancer care with their cutting-edge approaches and pioneering therapies.
OS Therapies Inc. (NYSEAmerican: OSTX) is gaining attention in the biotech space for…
![Bill Eiland's Innovative Approach to Medical Malpractice Cases Gains National Attention](https://cdn.open-pr.com/X/9/X912551112_g.jpg)
Bill Eiland's Innovative Approach to Medical Malpractice Cases Gains National At …
Bill Eiland's innovative approach to medical malpractice cases has garnered national recognition for its effectiveness and transformative impact on the field of legal practice. By integrating advanced technology, data analysis, and expert evidence into his personal injury law firm's methods, Eiland has established a new standard of excellence.
In the specialized realm of medical malpractice law, effective representation requires a blend of expertise, innovation, and strategic thinking. Bill Eiland, a prominent…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
Oncology Nutrition Market led to an unprecedented rise by 2025 : liver cancer, p …
Global Oncology Nutrition Market: Overview
Cancer diagnosis creates myriad questions about diet and nutrition. Those pertain to if the food will make a patient feel sick to what should be ingested to fight cancer. This has spawned the oncology nutrition market which has been rising steadily due to the increasing cases of different types of cancer worldwide. During cancer treatment one needs to eat right in order to build up strength…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports.
This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.
This report focuses on top…